Since April 17, 2018, the company name “Zhejiang Weixin BioPharm (Zhejiang) Co., Ltd.”has been changed to “Aimei Weixin BioPharm (Zhejiang) Co., Ltd.” Originally established in 2002, Aimei Weixin BioPharm (Zhejiang) Co., Ltd. (“AIM Weixin”) is a subsidiary of AIM Vaccine Co., Ltd. It is a high and new technology enterprise specializing in the scientific research & development and production of vaccines and related biological products.

With a registered capital of RMB 515,306,120, AIM Weixin covers an area of 41263㎡ and employs 254 people, with technicians accounting for above 70% of its staff. It owns domestic first-class research & test instrument and production equipment and facilities. Since its establishment, AIM Weixin has received generous support from the Ningbo government as a recognized high and new technology enterprise significantly supported and prioritized by Ningbo. The Company has established extensive collaboration with domestic and foreign scientific research institutes and universities on projects and technology development.

At present, AIM Weixin has four major vaccine products: live attenuated parotitis vaccine, inactivated bivalent HFRS vaccine (Vero cell), ACYW135 meningococcus polysaccharide vaccine, and HITB combined vaccine (Hib). Its live attenuated parotitis vaccine obtained a permit for production in October 2004, and passed the national GMP certification in January 2005. With a total workshop area of 2340㎡ and an annual production scale of 16 million vials, this product has been sold nationwide (25 provinces and municipalities including Heilongjiang, Jilin, Liaoning, Hebei, Tianjin, Shandong, Shanxi, Shaanxi, Hubei, Hunan, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Sichuan, Gansu, Qinghai, Inner Mongolia, Ningxia, Xinjiang, Yunnan, Jiangxi and Chongqing) with over 5 million vials used accumulatively. Due to its high titer level and high safety level, the live attenuated parotitis vaccine of AIM Weixin has won the trust of users, and gradually established a good brand reputation in China, with a market occupancy of above 70%. In September 2007, the inactivated bivalent HFRS vaccine (Vero cell) of AIM Weixin obtained a new drug certificate and a production permit from the National Medical Products Administration. Using WHO-approved Vero cells rather than primary animal cells, this vaccine is safe and reliable, and can be mass produced with neither environmental pollution due to animal breeding nor potential exogenous hazards brought by animal cells. With the adoption of advanced production techniques and the application of modern biotechnology and purification process, it has achieved high purity, good immunogenicity, safety, effectiveness and stable quality, representing the advanced level of similar vaccines in China at present. It can be used in epidemic areas of type I or type II HFRS and mixed epidemic areas of type I & II HFRS. With a broad immunization coverage, it is nowadays the most widely used vaccine for HFRS prevention. AIM Weixin’s ACYW135 meningococcus polysaccharide vaccine obtained its new drug certificate and GMP certificate in November 2018, and was put into the market in March 2020. The group A, C, Y and W135 Neisseria meningitidis strains used by this vaccine are from the National Institutes for Food and Drug Control in compliance with the results of China’s epidemiological surveys on Neisseria meningitidis, and can prevent epidemic cerebrospinal meningitis caused by group A, C, Y and W135 Neisseria meningitidis. This vaccine adopts the classic capsular polysaccharide purification process, which is the conventical preparation method for bacterial polysaccharide vaccines due to its stability and reliability. As a substitute for group A meningococcal polysaccharide vaccine (Class 1 vaccine) and group A+C meningococcal polysaccharide vaccine, AIM Weixin’s ACYW135 meningococcus polysaccharide vaccine has good market prospect.

In the future, AIM Weixin will enrich its product variety by optimizing production process, improving product quality and increasing R&D investment, so as to further enhance its core competitiveness. Also, it plans to introduce and attract outstanding talent to the Company through various methods, and establish a corresponding talent incentive plan to maintain the enthusiasm and motivation of its staff at work. Always striving for the highest quality, with leapfrog development and care for the society as its purposes, Aimei Weixin BioPharm (Zhejiang) Co., Ltd. seeks cooperation on the basis of mutual benefit and joint development, continues to optimize its industrial structure and allocation of human resources, and looks forward to establishing extensive partnerships and together creating brilliance with comrades from all sectors of the society.